

REC No	IRAS No	Name of Trial	Target Number Of Patients Agreed?	Minimum Number Of Patients Agreed (Enter Same In Both If Only One Number)	Maximum Number Of Patients Agreed (Enter Same In Both If Only One Number)	Target Date To Recruit Patients Agreed?	Date Agreed to recruit target number of patients	Total Number Of Patients Recruited At The Agreed Target Date	Date That The Trial Closed To Recruitment	Total Number Of Study Participants Recruited	Reason For Closure Of Trial
12/EM/0308	112289	A multicentre, double-blind and open label, 2 year extension study of subcutaneous secukinumab in prefilled syringes, assessing long-term safety, tolerability and efficacy in subjects with moderate to severe chronic plaque-type psoriasis treated with	Number Agreed	2	2	Date Agreed	06/02/2017	2	06/02/2017	2	Recruitment Finished
13/NW/0006	114825	A randomized, double-blind, placebo-controlled, phase 3 study of brentuximab vedotin and CHP (A+CHP) versus CHOP in the frontline treatment of patients with CD30-positive mature T-cell lymphomas	Number Agreed	2	2	Date Agreed	08/11/2016	0	08/11/2016	0	Recruitment Finished
13/EM/0251	131150	RELAX 2 - Serelaxin when added to standard therapy in acute heart failure	Number Agreed	6	6	Date Agreed	03/08/2016	13	03/08/2016	13	Recruitment Finished
13/NW/0692	134662	A multicenter, international, randomized, parallel group, double blind, placebo-controlled Cardiovascular Safety & Renal Microvascular outcome with LINagliptin, 5 mg once daily in patients with type 2 diabetes mellitus at high vascular risk. CARMELIN	Number Agreed	10	10	Date Agreed	20/07/2016	11	20/07/2016	11	Recruitment Finished
14/EM/0143	152568	A multi-centre, open-label, study of Mepolizumab in a subset of subjects with a history of life threatening/seriously debilitating asthma who participated in the MEA115661 Trial	Number Agreed	6	6	Date Agreed	10/01/2017	5	10/01/2017	5	Recruitment Finished
14/NE/1018	150960	A randomised, double-blind, placebo-controlled, parallel group, multicentre, phase III study to evaluate the efficacy and safety of 2 doses of benralizumab (MEDI-563) in patients with severe to very severe Chronic Obstructive Pulmonary Disease (COPD)	Number Agreed	6	6	Date Agreed	03/11/2016	19	03/11/2016	19	Recruitment Finished
14/WM/1055	152229	A prospective, multicenter, randomized, double blind, placebo-controlled, 2-parallel groups, phase 3 study to compare the efficacy and safety of masitinib in combination with FOLFIRI (irinotecan, 5-fluorouracil and folic acid) to placebo in combinat	Number Agreed	5	5	Date Agreed	22/11/2016	2	22/11/2016	2	Recruitment Finished
14/NE/1072	153275	A Phase II, Randomised, Double Blind, Placebo-controlled Bronchoscopy study to evaluate the effects of Lebrikizumab on airway eosinophilic inflammation in patients with uncontrolled asthma on inhaled corticosteroids and a second controller medication	Number Agreed	4	4	Date Agreed	04/08/2016	6	04/08/2016	6	Recruitment Finished
14/EE/1001	156001	A 6month, prospective, randomized, multicenter, placebo-controlled safety study of OTO-104 by intratympanic injection in subjects with unilateral Meniere's disease, followed by a 6month open-label extension	Number Agreed	6	6	Date Agreed	26/07/2016	2	26/07/2016	2	Recruitment Finished
13/NE/0125	119485	MCRN245 (NEO.1.C/E)	Number Agreed	1	1	Date Agreed	31/12/2016	1	31/12/2016	1	Recruitment Finished
14/SS/1048	154401	A Phase 3b, Multicenter, Randomized-withdrawal, Placebo-controlled, Double-blind, Parallel-group Trial to Compare the Efficacy and Safety of Tolvaptan (45 to 120 mg/day, Splitdose) in Subjects with Chronic Kidney Disease Between Late Stage 2 to Earl	Number Agreed	5	5	Date Agreed	31/03/2017	6	31/03/2017	6	Recruitment Finished
14/EM/1060	152584	A Phase 3 Open Label Extension Study of Fostamatinib Disodium in the Treatment of Persistent/Chronic Immune Thrombocytopenic Purpura	Number Agreed	1	1	Date Agreed	20/01/2017	2	20/01/2017	2	Recruitment Finished
14/NE/1214	162696	ABBVIE - M14-359	Number Agreed	5	5	Date Agreed	28/07/2016	8	28/07/2016	8	Recruitment Finished
14/SC/1311	155403	MCRN3165 (SD744) Cubist PSI Osteomyelitis	Number Agreed	1	1	Date Agreed	04/07/2016	0	04/07/2016	0	Recruitment Finished
15/WM/0009	165367	A Phase 3, Randomised, Controlled, Open-label Study of VELCADE (Bortezomib) Melphalan-Prednisone (VMP) Compared to Daratumumab in Combination with VMP (D-VMP), in Subjects with Previously Untreated Multiple Myeloma who are Ineligible for High-dose Th	Number Agreed	3	3	Date Agreed	15/07/2016	0	15/07/2016	0	Recruitment Finished
14/LO/1193	151954	3345 CARD STRENGTH	Number Agreed	5	5	Date Agreed	03/08/2016	0	03/08/2016	0	Recruitment Finished
15/LO/0691	174324	Checkmate 171: An Open-Label, Multicenter Clinical Trial with Nivolumab (BMS-936558) Monotherapy in Subjects with Advanced or Metastatic Squamous Cell (Sq) Non-Small Cell Lung Cancer (NSCLC) who Have Received at Least One Prior Systemic Regimen for t	Number Agreed	8	8	Date Agreed	06/07/2016	15	06/07/2016	15	Recruitment Finished
14/EM/1267	166568	A multicenter study to evaluate safety and tolerability in patients with chronic heart failure and reduced ejection fraction	Number Agreed	5	5	Date Agreed	31/07/2016	5	31/07/2016	5	Recruitment Finished

REC No	IRAS No	Name of Trial	Target Number Of Patients Agreed?	Minimum Number Of Patients Agreed (Enter Same In Both If Only One Number)	Maximum Number Of Patients Agreed (Enter Same In Both If Only One Number)	Target Date To Recruit Patients Agreed?	Date Agreed to recruit target number of patients	Total Number Of Patients Recruited At The Agreed Target Date	Date That The Trial Closed To Recruitment	Total Number Of Study Participants Recruited	Reason For Closure Of Trial
15/EE/0161	177265	A Phase III, randomised, double blind, placebo-controlled, parallel group, efficacy, safety and tolerability trial of Empagliflozin as Adjunctive to insulin over 52 weeks in patients with Type 1 Diabetes Mellitus (EASE-2)	Number Agreed	5	5	Date Agreed	26/09/2016	6	26/09/2016	6	Recruitment Finished
14/NW/0218	149200	GLYCEMIC CONTROL AND TREATMENT SATISFACTION USING FINESSE VERSUS PEN FOR INITIATING BOLUS INSULIN DOSING IN TYPE 2 DIABETES MELLITUS PATIENTS NOT ACHIEVING GLYCEMIC TARGETS ON BASAL INSULIN WITH/WITHOUT ANTI-HYPERGLYCEMIC AGENTS	Number Agreed	5	5	Date Agreed	24/08/2016	3	24/08/2016	3	Recruitment Finished
15/LO/0861	179571	RESP 4558	Number Agreed	4	4	Date Agreed	01/12/2016	4	01/12/2016	4	Recruitment Finished
15/NW/0152	169540	CANC - 4235 - Herceptin + Perjeta +Docetaxel in HER2-Positive advanced breast cancer - MetaPHer	Number Agreed	15	15	Date Agreed	03/02/2017	3	03/02/2017	3	Recruitment Finished
15/EM/0247	179169	Effect of Tralokinumab on Airway Inflammation in Asthma	Number Agreed	6	6	Date Agreed	30/11/2016	8	30/11/2016	8	Recruitment Finished
15/LO/0519	176955	A Multiarm-arm Phase 3 Randomized Placebo Controlled Double Blind Clinical Trial to Investigate the Efficacy and Safety of BMS-663068 in Heavily Treatment Experienced Subjects Infected with Multi-drug Resistant HIV-1	Number Agreed	2	2	Date Agreed	15/07/2016	0	15/07/2016	0	Recruitment Finished
15/NW/0668	173723	FUTURE 5: A phase III, randomised, double-blind, placebo controlled multicentre study of subcutaneous secukinumab (150 mg and 300 mg) in prefilled syringe to demonstrate efficiency (including inhibition of structural damage), safety and tolerability	Number Agreed	10	10	Date Agreed	27/09/2016	2	27/09/2016	2	Recruitment Finished
15/EM/0344	183906	A Randomized, Double-blind, Placebo-controlled Study of the Safety and Efficacy of Amatuximab in Combination with Pemetrexed and Cisplatin in Subjects with Unresectable Malignant Pleural Mesothelioma	Number Agreed	5	5	Date Agreed	13/01/2017	8	13/01/2017	8	Recruitment Finished
14/LO/2011	159926	DUAL antithrombotic therapy with dabigatran etexilate (RE-DUAL PCI)	Number Agreed	10	10	Date Agreed	31/10/2016	2	31/10/2016	2	Recruitment Finished
15/NW/0468	182025	A Randomized, Multicenter, Open-Label, 3 Arm Phase 3 Study of Obinutuzumab in Combination with Chlorambucil, ACP-196 inCombination with Obinutuzumab, and ACP-196 Monotherapy in Subjects with Previously Untreated Chronic Lymphocytic Leukemia	Number Agreed	3	3	Date Agreed	13/03/2017	3	13/03/2017	3	Recruitment Finished
15/SC/0475	174852	An Open-Label, Randomized Phase 3 Trial of Nivolumab and Nivolumab plus Ipilimumab versus Platinum Doublet Chemotherapy in Patients with Chemotherapy-Na?ve Stage IV or Recurrent Non-Small Cell Lung Cancer (NSCLC)	Not Available / Not Agreed			Date Agreed	30/11/2016	14	30/11/2016	14	Recruitment Finished
11/SC/0059	74662	INCA 2201, INC 424 - A Phase IB, Open-Label, Dose-Finding Study Of The JAK-inhibitor INC424 Tablets Administered Orally to Patients With Primary Myelofibrosis (PMF), Post-Polycythemia Vera-Myelofibrosis (PPV-MF) Or Post-Essential Thrombocythemia-Myel	Number Agreed	2	2	Date Agreed	13/01/2017	0	13/01/2017	0	Recruitment Finished
15/EM/0473	187884	Phase II trial of anetumab ravtansine (BAY 94-9343) in patients with advanced or metastatic malignant pleural mesothelioma (MPM) overexpressing mesothelin after first line treatment with platinum in combination with pemetrexed	Number Agreed	4	4	Date Agreed	16/12/2016	5	16/12/2016	5	Recruitment Finished
15/LO/2066	193084	4222: Efficacy And Long-Term Safety Of Oral Semaglutide Versus Sitagliptin In Subjects With Type 2 Diabetes Mellitus. A 78-Week, Randomised, Double-Blind, Double-Dummy, Active-Controlled, Parallel-Group, Multi-Centre, Multi-National, Four-Armed Tria	Number Agreed	4	4	Date Agreed	10/07/2016	5	10/07/2016	5	Recruitment Finished
16/LO/0152	193306	DIAB 5013 A real-world, point of care, randomized, 2-arm, open, 52-week study to evaluate the effect of a digital disease management support tool in patients with type 2 diabetes mellitus.	Number Agreed	25	25	Date Agreed	14/10/2016	14	14/10/2016	14	Recruitment Finished
15/LO/1500	187068	Drug-drug interaction study with nintedanib and pirfenidone	Number Agreed	4	4	Date Agreed	06/03/2017	2	06/03/2017	2	Recruitment Finished
15/NW/0626	184626	A Phase 3, Randomized, Double-blind, Placebocontrolled, Parallel-group, Multicenter Study to Evaluate the Net Clinical Benefit of Sotagliflozin as Adjunct to Insulin Therapy in Type 1 Diabetes	Number Agreed	5	5	Date Agreed	19/08/2016	1	19/08/2016	1	Recruitment Finished

REC No	IRAS No	Name of Trial	Target Number Of Patients Agreed?	Minimum Number Of Patients Agreed (Enter Same In Both If Only One Number)	Maximum Number Of Patients Agreed (Enter Same In Both If Only One Number)	Target Date To Recruit Patients Agreed?	Date Agreed to recruit target number of patients	Total Number Of Patients Recruited At The Agreed Target Date	Date That The Trial Closed To Recruitment	Total Number Of Study Participants Recruited	Reason For Closure Of Trial
16/EM/0006	191553	A 24 week, Multicentre, Randomized, Open Label, 2 ARm Parallel-group study evaluating the Efficacy and Safety of Patient - versus Physician-managed Titration of Insulin Glargine U300 in Type 2 Diabetes Mellitus	Number Agreed	10	10	Date Agreed	01/12/2016	9	01/12/2016	9	Recruitment Finished
16/NE/0014	192732	AF219-012: A 12-Week Study to Assess the Efficacy and Safety of AF-219 in Subjects with Treatment Refractory Chronic Cough	Number Agreed	6	6	Date Agreed	28/07/2016	9	28/07/2016	9	Recruitment Finished
16/NW/0169	196447	An open-label, randomised, phase II study comparing TAS-102 plus bevacizumab to capecitabine plus bevacizumab in patients with previously untreated metastatic colorectal cancer who are eligible for non-intensive therapy	Number Agreed	12	12	Date Agreed	27/02/2017	2	27/02/2017	2	Recruitment Finished
15/SC/0699	192903	Clinical Study Protocol M13-549 A Phase 3, Randomized, Double-Blind Study Comparing ABT-494 to Placebo in Subjects with Moderately to Severely Active Rheumatoid Arthritis Who Are on a Stable Dose of Conventional Synthetic Disease-Modifying Anti-Rheum	Number Agreed	3	3	Date Agreed	22/12/2016	1	22/12/2016	1	Recruitment Finished
16/LO/0448	198164	A Phase 2 Study of LY2606368 in patients with extensive stage disease small cell lung cancer.	Number Agreed	2	2	Date Agreed	18/01/2017	1	18/01/2017	1	Recruitment Finished
16/SC/0336	208403	Utilizing Novel dipole density Capabilities to Objectively Visualize the Etiology of Rhythms in Atrial Fibrillation (UNCOVER-AF)	Number Agreed	10	10	Date Agreed	01/03/2017	1	01/03/2017	1	Recruitment Finished
15/EE/0350	187779	A Phase III, randomised, double blind, placebo-controlled, parallel group, efficacy, safety and tolerability trial of once daily, oral doses of Empagliflozin as Adjunctive to insulin therapy over 26 weeks in patients with Type 1 Diabetes Mellitus (EAS)	Number Agreed	3	3	Date Agreed	21/12/2016	0	21/12/2016	0	Recruitment Finished
13/EE/0345	135062	Multi-arm, non-randomised, open-label phase 1B study to evaluate GSK3052230 in combination with paclitaxel and carboplatin, or docetaxel or as single agent in subjects with solid malignancies and deregulated FGF pathway signalling	Not Available / Not Agreed			Date Agreed	02/08/2016	2	02/08/2016	2	Recruitment Finished
13/NE/0005	100377	Product Surveillance Registry A prospective, noninterventional registry providing continuing evaluation and periodic reporting of product safety, effectiveness and patient outcomes across Medtronic marketreleased products within diabetes, cardia	Number Agreed	5	5	Date Agreed	03/07/2017	3	30/06/2017	3	Recruitment Finished
14/EM/0186	150545	A Randomized Controlled Phase 3 Study of Oral Pacritinib versus Best Available Therapy in Patients with Thrombocytopenia and Primary Myelofibrosis, Post-Polycythemia Vera Myelofibrosis, or Post-Essential Thrombocythemia Myelofibrosis	Number Agreed	2	2	Date Agreed	10/04/2017	2	10/04/2017	2	Recruitment Finished
15/LO/1807	187302	An Open-label, Randomized, Phase 3 Study of Nivolumab, Nivolumab combined with Ipilimumab, or Chemotherapy in Subjects with Relapsed Small-cell Lung Cancer after Platinumbased First Line Chemotherapy	Not Available / Not Agreed			Date Agreed	26/09/2016	0	26/09/2016	0	Recruitment Finished
15/LO/1236	183416	A Phase 3, Randomized, Multicenter, DoubleBlind, PlaceboControlled, 2Arm, Efficacy and Safety Study of NEOD001 Plus Standard of Care vs. Placebo Plus Standard of Care in Subjects with Light Chain (AL) Amyloidosis	Number Agreed	2	2	Date Agreed	18/05/2017	0	18/05/2017	0	Recruitment Finished
16/EE/0048	192528	A two-arm, randomised, assessor-blind, parallel group study to evaluate the effect of fluticasone/formoterol breath actuated inhaler (BAI) and Relvar Ellipta DPI on ventilation heterogeneity in subjects with partially controlled or uncontrolled asthma	Number Agreed	7	7	Date Agreed	28/04/2017	4	28/04/2017	4	Recruitment Finished
16/LO/1450	202124	A Phase 3, Multicenter, Randomized, Double Blind Study of Bortezomib and Dexamethasone in Combination with Either Venetoclax or Placebo in Subjects with Relapsed or Refractory Multiple Myeloma Who are Sensitive or Na?ve to Proteasome Inhibitors	Number Agreed	6	6	Date Agreed	17/05/2017	5	17/05/2017	5	Recruitment Finished